Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2020
Reporting Period: Event-based report regarding a specific corporate announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a clinical trial update rather than financial performance.
Material Changes
No material financial changes were reported. The primary event is the announcement of upcoming interim data from a Phase Ib clinical study.
Outlook, Management Commentary, and Risks
- Clinical Update: The Company announced it will report interim data next week from its Phase Ib clinical study of XPro1595 in Alzheimer's disease.
- Exhibit: A press release dated July 9, 2020, detailing this announcement is attached as Exhibit 99.1.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the release date and content of the interim data for the XPro1595 Phase Ib study in Alzheimer's disease.
- Review the full text of the press release attached as Exhibit 99.1 for specific trial endpoints and results.
- Monitor subsequent filings for the actual data release and any impact on the Company's stock price or development timeline.